Melanotan and melanocortin research: the evidence
Melanotan II is a synthetic analogue of alpha-melanocyte stimulating hormone, one of a family of melanocortin peptides whose best-studied member reached randomized trials and regulatory approval. Here is what the published research shows, and which molecule each result belongs to.
Findings
- Two randomized, placebo-controlled trials of afamelanotide, a different analogue of the same natural hormone, covered 168 patients across the European Union and the United States.
- Pain-free time in direct sunlight rose from a median of 40.8 to 69.4 hours over six months in the United States trial (p=0.04).
- Phototoxic reactions over nine months fell from 146 to 77 in the European trial (p=0.04), and quality of life improved in both.
- Afamelanotide went on to approval as an orphan drug, the first melanocortin analogue of its kind to do so.
- For Melanotan II specifically, the published work is laboratory and early-stage research, not randomized trials. That distinction matters when reading claims about this family.
The randomized evidence belongs to afamelanotide (N Engl J Med, 2015)
Two multicentre, randomized, double-blind, placebo-controlled trials tested subcutaneous implants containing 16 mg of afamelanotide in patients with erythropoietic protoporphyria, a disorder in which sunlight causes severe pain. Seventy-four patients in the European Union and 94 in the United States were assigned one-to-one to afamelanotide or placebo, with implants every 60 days. The primary measure was hours of direct sunlight exposure without pain. In the United States study, median pain-free time after six months was 69.4 hours against 40.8 on placebo (p=0.04). In the European study, median pain-free time after nine months was 6.0 hours against 0.8 (p=0.005), and the number of phototoxic reactions was lower on afamelanotide (77 against 146, p=0.04). Quality of life improved in both trials.
Why afamelanotide and Melanotan II are not the same molecule
Both are synthetic analogues of alpha-melanocyte stimulating hormone, the natural human hormone, but they are different compounds with different structures. Afamelanotide is a linear analogue that went through the trial programme above. Melanotan II is a cyclic analogue, developed earlier in university research on melanocortin receptors, and it is the one supplied as a research material. It binds a broader set of melanocortin receptors than afamelanotide does, which is why the two have been studied for different effects. Published work specific to Melanotan II is laboratory and early-stage human research rather than randomized trials, and any result quoted from the afamelanotide programme belongs to that molecule, not to this one.
The receptor family behind both
Melanocortin peptides act at five receptor subtypes. MC1R, on pigment cells, is the one behind the sunlight results above. MC4R, in the brain, is the subtype involved in appetite and in sexual response, and it is the target of bremelanotide, another peptide in this family that reached approval for a separate use. That one family of receptors covers pigmentation, inflammation, appetite and sexual response is why melanocortin research runs across so many fields at once, and why results for one analogue say little about another.
What Melanotan II is
Melanotan II is a cyclic seven-amino-acid analogue of alpha-melanocyte stimulating hormone, supplied as a lyophilised powder for laboratory research. It is studied for its activity at melanocortin receptors, which is where the comparison with the molecules above begins and ends: the trial results described on this page were obtained with afamelanotide. Our reconstitution guide covers handling of the vialled material.
Vistara Labs stocks Melanotan II research vials and a ready-mixed Melanotan II nasal spray, shipped from within Canada to every province.
Frequently asked questions
Has Melanotan II itself been through randomized trials?
No. The large randomized trials in this family were run on afamelanotide, a different synthetic analogue of the same natural hormone. Melanotan II is the research analogue, and the published work specific to it is laboratory and early-stage research.
What did the afamelanotide trials show?
In two randomized, placebo-controlled trials covering 168 patients with a light-sensitivity disorder, pain-free time in direct sunlight rose from a median of 40.8 to 69.4 hours over six months in the United States study (p=0.04), and phototoxic reactions fell from 146 to 77 in the European study (p=0.04).
What is Melanotan II?
Melanotan II is a synthetic cyclic analogue of alpha-melanocyte stimulating hormone, the natural hormone that signals through the melanocortin receptors. Those receptors are involved in pigmentation, inflammation and, through a different receptor subtype, sexual response.
Sources: Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48-59. PMID 26132941. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2015;8:43-53. PMID 25470471. Wu J, Bhandari A. Afamelanotide: an orphan drug with potential for broad dermatologic applications. J Drugs Dermatol. 2021;20:290-294. PMID 33683075.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.